NEW YORK and PORTLAND, Ore., Oct. 22, 2015 /PRNewswire/ -- Wellpartner, Inc. encourages covered entities to add their voice to the debate on the draft 340B mega-guidance before the Tuesday, October 27, 2015 deadline.
Wellpartner has developed a Proposed Mega-Guidance Comparison Guide to help 340B-covered entities understand the current and proposed guidance. This comparison guide provides a thorough review and explanation of the updates.
Wellpartner recommends that covered entities submit factual evidence and commentary directly to 340B Health about how the 340B Program benefits their community. The Mega-Guidance Resource center also has tools, surveys, and webinars available to help covered entities prepare comments. Comments can also be submitted to HRSA through the Federal eRulemaking Portal.
Wellpartner is a leading national provider of complete 340B optimization solutions for a wide variety of safety-net hospitals and clinics. Wellpartner dispenses pharmaceutical and specialty products through its wholly owned URAC, ACHC, and VIPPS-accredited specialty pharmacy.
Wellpartner's products include:
- 340BAccess™, an automated solution for covered entities seeking a 340B contract pharmacy program;
- AccessConvergence™, which enables clients to greatly enhance their 340B programs by gaining access to previously "locked-away" specialty pharmaceutical prescriptions;
- AccessIntegra®, a state-of-the-art reporting and analytics tool that provides a transparent view into a covered entity's 340B contract pharmacy program; and
- AccessCompare®, the industry's first 340B reporting tool that helps covered entities meet increasing program integrity audit requirements by reducing the manual time needed to efficiently audit 340B claims.
Visit www.wellpartner.com for more information.